-
-
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
-
-
p53 immunohistochemistry in endometrial cancer
-
-
Radiotherapy quality assurance in the PORTEC-3 (TROG 08.04) trial
-
-
Radiation therapy techniques and treatment-related toxicity in the PORTEC-3 trial
-
-
Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial
-
-
Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial
-
-
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
-
-
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3)
-
-
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
-
-
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
-
-
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
-
-
Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial
-
-
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
-
-
RELATION BETWEEN PATIENT AND PHYSICIAN REPORTED TOXICITY IN THE RANDOMISED PORTEC-3 TRIAL OF RADIATION THERAPY (RT) WITH OR WITHOUT CHEMOTHERAPY FOR ENDOMETRIAL CANCER
-
-
Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial
-
-
PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN AN ANZGOG SUBSTUDY OF THE PORTEC-3 INTERGROUP RANDOMIZED CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY IN HIGH RISK ENDOMETRIAL CANCER
